Seretide/Advair is GSK’s best-selling drug, and the line was extended in 2003 when the European Union approved the higher-dose 500 Accuhaler for the symptomatic treatment of severe COPD, i.e., ...
GlaxoSmithKline said yesterday its combination asthma drug Seretide had become the first drug to reduce the risk of death in patients with chronic obstructive pulmonary disease (COPD). GlaxoSmithKline ...